Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary

Genprex (NASDAQ: GNPX) said collaborators will present positive preclinical data for Reqorsa® gene therapy (quaratusugene ozeplasmid) for ALK-EML4 positive non-small cell lung cancer at the 2025 AACR-NCI-EROTC conference in Boston.

The poster from the University of Michigan Rogel Cancer Center will be shown on October 25, 2025 (12:30–4:00 p.m. ET) and reports TUSC2 upregulation by Reqorsa inducing apoptosis in EML4-ALK bearing NSCLC in preclinical studies. Genprex cited a Sponsored Research Agreement from October 2024 with the University of Michigan and noted co-sponsorship by patient group ALK Positive. Laboratory data reported tumor-cell uptake of TUSC2 after Reqorsa treatment at 10–33x versus normal cells.

Insights

Translational oncology analyst

Positive preclinical data reported for REQORSA in ALK-EML4 NSCLC; results remain early and preclinical only.

Genprex-supported collaborators at The University of Michigan Rogel Cancer Center present data showing that quaratusugene ozeplasmid (REQORSA) upregulates the tumor suppressor TUSC2 and induces apoptosis in ALK-EML4 bearing non-small cell lung carcinoma in preclinical models. The program uses the company’s Oncoprex® lipoplex delivery system and reports tumor-cell uptake of TUSC2 that is "10 to 33 times" higher than in normal cells, which the release cites as a specificity metric.

These findings validate a biological mechanism in laboratory models but remain preclinical and do not demonstrate safety or efficacy in humans. The work stems from a October 2024 Sponsored Research Agreement and a patient-organization collaboration; results will be presented at the conference on October 25, 2025. Watch for peer-reviewed data details in the poster and any disclosed experimental controls, sample sizes, and replication over the coming conference window (October 22-26, 2025), as those items materially affect translational relevance.

Reqorsa^® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer

AUSTIN, Texas, Oct. 14, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 at the Hynes Convention Center in Boston. The collaborators will present positive preclinical data from a study of Genprex's lead drug candidate, Reqorsa^® Gene Therapy (quaratusugene ozeplasmid), for the treatment of ALK-EML4 positive non-small cell lung cancer (NSCLC).

"We are thrilled that our collaborators have once again been selected to present positive preclinical data on the use of REQORSA and its ability to induce apoptosis in ALK positive lung cancer, a subset of NSCLC that impacts mostly young, non-smoking individuals," said Ryan Confer, President and Chief Executive Officer at Genprex. "These preclinical data further validate REQORSA as a potential treatment for many types of cancer, including another subset of lung cancer, and we look forward to continuing our studies of REQORSA in combination with ALK inhibitors."

The featured Genprex-supported poster to be presented at the 2025 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics:

Title: "Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies"

Collaborator: The University of Michigan Rogel Cancer Center

Session: Poster Session C

Session Date and Time: Saturday, October 25, 2025 from 12:30 – 4:00 p.m. ET

Genprex entered into a Sponsored Research Agreement (SRA) with the University of Michigan Rogel Cancer Center in October 2024 to study TUSC2, the tumor suppressor gene used in REQORSA, in combination with ALK-inhibitors in ALK-EML4 positive translocated lung cancer. Also in October 2024, Genprex announced its collaboration with ALK Positive, a non-profit patient-driven research organization dedicated to improving the life expectancy and quality of life for ALK-positive lung cancer patients, which shares in sponsoring this preclinical study.

TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex^® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex^® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa^® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; including as a potential treatment for ALK-EML4 positive translocated non-small cell lung cancer; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com 

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics-302582836.html

SOURCE Genprex, Inc.

FAQ

What preclinical results will Genprex (GNPX) present on October 25, 2025?

A University of Michigan poster will present positive preclinical data showing Reqorsa-mediated TUSC2 upregulation induces apoptosis in EML4-ALK positive NSCLC.

When and where will Genprex collaborators present the Reqorsa data at the 2025 conference?

The poster session is scheduled for October 25, 2025 from 12:30–4:00 p.m. ET at the Hynes Convention Center in Boston.

What is Reqorsa (quaratusugene ozeplasmid) and its target for the GNPX presentation?

Reqorsa is a TUSC2-expressing plasmid in lipid nanoparticles designed to deliver the tumor suppressor TUSC2 to ALK-EML4 positive NSCLC cells.

How much greater was TUSC2 uptake in tumor cells after Reqorsa treatment reported by Genprex?

Laboratory studies reported tumor-cell uptake of TUSC2 was 10 to 33 times higher than uptake in normal cells after Reqorsa treatment.

What collaborations supported the preclinical ALK-EML4 lung cancer study for GNPX?

Genprex entered a Sponsored Research Agreement in October 2024 with University of Michigan Rogel Cancer Center and co-sponsorship from patient group ALK Positive.

Does the Genprex (GNPX) announcement include clinical efficacy or near-term regulatory updates?

No; the announcement describes positive preclinical data and collaborations but does not report clinical trial results or regulatory actions.